Literature DB >> 30808985

Immunometabolism and natural killer cell responses.

Katie L O'Brien1, David K Finlay2,3.   

Abstract

Natural killer (NK) cells are lymphocytes with important roles in innate and adaptive immune responses to tumours and viral infection. However, in certain chronic diseases, including obesity and cancer, NK cell functional responses are impaired. Recently, research has highlighted the importance of NK cell metabolism in facilitating robust NK cell effector functions. This Review describes our current understanding of mouse and human NK cell metabolism and the key signalling pathways that mediate metabolic responses in NK cells. Furthermore, it explores how defects in metabolism can contribute to the generation of dysfunctional NK cells in chronic disease. Finally, the potential for new therapeutic strategies targeting cellular metabolism is discussed.

Entities:  

Mesh:

Year:  2019        PMID: 30808985     DOI: 10.1038/s41577-019-0139-2

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  107 in total

1.  CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity.

Authors:  Meisam Naeimi Kararoudi; Yuya Nagai; Ezgi Elmas; Marcelo de Souza Fernandes Pereira; Syed Abbas Ali; Philip Hollingsworth Imus; Darren Wethington; Ivan Marques Borrello; Dean Anthony Lee; Gabriel Ghiaur
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

2.  NK and NKT-like cells in granulomatous and fibrotic lung diseases.

Authors:  L Bergantini; P Cameli; M d'Alessandro; C Vagaggini; R M Refini; C Landi; M G Pieroni; M Spalletti; P Sestini; E Bargagli
Journal:  Clin Exp Med       Date:  2019-09-04       Impact factor: 3.984

Review 3.  Lipid Metabolism in Tumor-Associated Natural Killer Cells.

Authors:  Yu Chen; Meihua Sui
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironment-like Conditions.

Authors:  Luke Maggs; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2020-06-22       Impact factor: 12.531

Review 5.  Immunometabolism and HIV-1 pathogenesis: food for thought.

Authors:  Asier Sáez-Cirión; Irini Sereti
Journal:  Nat Rev Immunol       Date:  2020-08-06       Impact factor: 53.106

6.  Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.

Authors:  Huang Zhu; Robert H Blum; Davide Bernareggi; Eivind Heggernes Ask; Zhengming Wu; Hanna Julie Hoel; Zhipeng Meng; Chengsheng Wu; Kun-Liang Guan; Karl-Johan Malmberg; Dan S Kaufman
Journal:  Cell Stem Cell       Date:  2020-06-11       Impact factor: 24.633

Review 7.  Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors.

Authors:  Hamid Khodayari; Saeed Khodayari; Elmira Ebrahimi; Farimah Hadjilooei; Miko Vesovic; Habibollah Mahmoodzadeh; Tomo Saric; Wilfried Stücker; Stefaan Van Gool; Jürgen Hescheler; Karim Nayernia
Journal:  Cancer Immunol Immunother       Date:  2021-07-04       Impact factor: 6.968

8.  Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance.

Authors:  Xiaohu Zheng; Yeben Qian; Binqing Fu; Defeng Jiao; Yong Jiang; Peng Chen; Yiqing Shen; Huafeng Zhang; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  Nat Immunol       Date:  2019-10-21       Impact factor: 25.606

Review 9.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

10.  Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO.

Authors:  Chantiya Chanswangphuwana; David S J Allan; Mala Chakraborty; Robert N Reger; Richard W Childs
Journal:  Mol Ther       Date:  2020-09-20       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.